Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
5-azacytidine, Valproic Acid, and ATRA for High-Risk MDS and AML
NCT00326170Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jul 2005
- Primary completion
- Jul 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of azacitidine, valproic acid and tretinoin in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), sponsored by University of Texas MD Anderson Cancer Center. Started Jul 2005; status: completed.
02
Drugs
azacitidinevalproic acidtretinoin
03
Conditions
myelodysplastic syndrome (MDS)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00326170.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00326170.